Prophylaxis News and Research

RSS

Novel peptide-antibody fusion molecule enhances SARS-CoV-2 variant neutralization

A recent study reports neutralizing efficacy for a fused peptide-antibody molecule against SARS-CoV-2, providing hope that therapeutic neutralizing antibodies may soon be available.

3 Dec 2021

New analysis highlights the global prevalence of HIV among transgender people

A new analysis highlights the prevalence of HIV among transgender individuals worldwide, and shows the need for continued prevention efforts for this population.

1 Dec 2021

World AIDS Day: New Vital Signs report highlights persistent disparities in HIV prevention and care

Despite overall progress in reducing new infections among gay and bisexual men, the HIV epidemic continued and was more severe among Black or African American (hereafter referred to as Black) and Hispanic/Latino gay and bisexual men in the decade leading up to the federal Ending the HIV Epidemic in the U.S. (EHE) initiative, which the U.S. Department of Health and Human Services launched in 2019.

1 Dec 2021

Microbiome research opens up new perspectives for healthy and climate-resilient crops

Agriculture is facing enormous challenges worldwide due to global changes caused by human activities. Drought, severe weather events, record temperatures and emerging pathogens threaten the world's food supply.

30 Nov 2021

Immunogenicity of modified microparticle-adjuvanted SARS-CoV-2 vaccine

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

29 Nov 2021

Scientists now close to eliminating mother-baby HIV transmission, says leading researcher

Quarraisha Abdool Karim has spent the past three decades studying HIV and AIDS. She has become one of the world's leading epidemiologists and made major contributions to the global understanding of how HIV affects young women.

24 Nov 2021

Donor cells with clonal hematopoiesis may improve bone marrow transplant outcomes

Clonal hematopoiesis, a condition in which mutations associated with blood cancers are found in the blood of healthy people, is common with aging.

22 Nov 2021

REGEN-COV is effective in preventing severe COVID-19 in immunocompromised individuals

A recent study assesses the efficacy of repeat doses of REGEN-COV in SARS-CoV-2-negative adults who were healthy or had chronic medical conditions.

18 Nov 2021

Study shows neutralizing capacity of monoclonal antibodies against SARS-CoV-2 variants of concern

Canadian public health researchers recently published a study in the journal Antiviral Research wherein they described generating a panel of murine hybridomas recognizing SARS-CoV-2 spike protein or nucleoprotein, capable of neutralizing the SARS-CoV-2 variants of concern, proving their therapeutic potential.

17 Nov 2021

Modeling the role of antivirals in suppressing the COVID-19 pandemic

A new study used an agent-based mathematical model to evaluate potential population impact on the widespread use of antiviral treatment for reducing viral load and hospitalization risk.

16 Nov 2021

Penicillin can prevent progression of latent rheumatic heart disease in children

A regular, affordable antibiotic treatment significantly reduced the risk of underlying rheumatic heart disease progression in children and adolescents, according to a new study.

14 Nov 2021

Analysis of immunodeficient patients granted REGEN-COV under compassionate use COVID-19 program

A team of scientists describe the safety and response to REGEN-COV® for COVID-19 patients with immunodeficiency-associated antibody disorders.

11 Nov 2021

REGEN-COV shown to rapidly reduce SARS-CoV-2 viral load in hospitalized COVID-19 patients

Studies have shown that mortality rates in hospitalized patients with COVID-19 are high, ranging between 10% and 30%. REGEN-COV®, a combination of monoclonal antibodies casirivimab and imdevimab, is approved in the United States and other regions for emergency treatment of COVID-19 outpatients with mild to moderate SARS-CoV-2 infection and post-exposure prophylaxis.

10 Nov 2021

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

2 Nov 2021

Compared to influenza, COVID-19 is more likely to cause venous thrombosis

New research published in the medRxiv* preprint server suggests that COVID-19 illness incurs a greater 90-day risk of venous thrombosis than the flu. However, arterial thrombosis remains a higher risk among people with the influenza virus.

24 Oct 2021

CDC lab testing identifies deadly bacteria in an aromatherapy spray

Laboratory testing at the U.S. Centers for Disease Control and Prevention (CDC) has identified the bacteria Burkholderia pseudomallei in an aromatherapy spray -; the same type of bacteria that sickened four people in the United States earlier this year.

22 Oct 2021

A mucoadhesive polymer with anti-SARS-COV-2 activity in vitro and in vivo

The team has evaluated a low molecular weight chitosan derivative as a candidate preventing the viral entry into mammalian nasal epithelial cells to limit the spread of COVID-19.

12 Oct 2021

Analysis shows dramatic fall in the number of people living with undiagnosed HIV in England

England is on track to have diagnosed 95% of people living with HIV by 2025, putting it in a strong position to eliminate HIV transmission by 2030, say researchers at the MRC Biostatistics Unit, University of Cambridge, and Public Health England (PHE).

24 Sep 2021

Johns Hopkins Medicine mathematical model to play major role in ending HIV nationwide

A new Johns Hopkins Medicine mathematical model to predict how the human immunodeficiency virus (HIV) spreads in urban areas will play a major role in a federal initiative aiming to reduce the incidence of HIV infections in the United States by 90% between 2020 and 2030.